Home / health news / Regeneron Pharmaceuticals Inc. (REGN) Receives $457.83 Average Target Price from Brokerages quoting : Sports Perspectives
alibaba.com, cpa campaign, lead generation, lead campaign, smart match lander, intelligent lander, a

Regeneron Pharmaceuticals Inc. (REGN) Receives $457.83 Average Target Price from Brokerages quoting : Sports Perspectives

referring to Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.
Morgan Stanley set a $370.00 target price on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Monday, January 9th.
Canaccord Genuity set a $450.00 target price on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Monday, December 12th.
The average 1-year target price among brokers that have covered the stock in the last year is $457.83.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has been given a consensus recommendation of “Buy” by the twenty-nine ratings firms that are currently covering the firm.

Regeneron Pharmaceuticals Inc. (REGN) Receives $457.83 Average Target Price from Brokerages

according to In other Regeneron Pharmaceuticals news, major shareholder Sanofi bought 87,298 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 11th.
COPYRIGHT VIOLATION NOTICE: “Regeneron Pharmaceuticals Inc. (REGN) Stock Rating Reaffirmed by JPMorgan Chase & Co.” was originally posted by Community Financial News and is owned by of Community Financial News.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “hold” rating reiterated by research analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Sunday.
Fifteen research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock.
Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $482.27.

according to

Regeneron Pharmaceuticals Inc. (REGN) Rises 4.29% for January 31

Starting the day trading at $344.05, Regeneron Pharmaceuticals Inc. reached an intraday high of $360.00 and hit intraday lows of $343.50.
Regeneron Pharmaceuticals Inc. has its corporate headquarters located in Tarrytown, NY and employs 4,300 people.
You can find a complete fundamental analysis of this stock at our For a complete fundamental analysis analysis of Regeneron Pharmaceuticals Inc., check out Stock Valuation Analysis tool for REGN.
Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company.
To get more information on Regeneron Pharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: REGN’s Profile.

about the details read more from here

This content may collect you by Luaren Colin

To follow all the new news about health

Check Also

picture.jpg

A new recommendation to reduce the number of shots for children of HPV vaccine

according to “This vaccine should have been introduced as a vaccine that will prevent cancer, …